Apparent Remission of a Solitary Metastatic Pulmonary Lesion in a Liver Transplant Recipient Treated with Sorafenib |
| |
| Authors: | M Yeganeh R S Finn S Saab |
| |
| Institution: | 1. Department of Medicine;2. Department of Surgery, University of California, Los Angeles, CA |
| |
| Abstract: | Hepatocellular carcinoma (HCC) remains a significant disease worldwide and its incidence is expected to increase. In selected patients, liver transplantation offers a 5‐year patient survival between 48% and 75%. However, HCC recurrence occurs in approximately 20% of transplant recipients. No therapy has proven efficacious in decreasing the risk of recurrence after transplantation. Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced HCC that have no history of liver transplantation. We report complete remission of HCC in a 54‐year‐old man who developed biopsy‐proven lung metastasis after liver transplantation treated with sorafenib. |
| |
| Keywords: | Hepatocellular carcinoma liver transplantation |
|
|
